Legal Featured Article
October 02, 2012
Openet Wins Summary Judgement in Patent Infringement Lawsuit
By Mandira Srivastava, TMCnet Contributor
Dublin-based telecoms software company Openet has secured the victory against the software service company, Amdocs, when the court concluded that Openet's (News - Alert) software does not infringe on patents owned by Amdoc.
The suit was filed in August 2010. In the patent-infringement lawsuit, Amdoc alleged that Openet infringed two U.S. patents related to Openet's mediation products, specifically its ability to gather, combine and synthesize vast quantities of data in complex networks and systems. In January 2011, two additional patents were added to Amdoc's original complaint.
The company attempted injunction related to Openet’s mediation products, specifically its ability to gather, combine and synthesize the huge quantities of data generated within the world’s largest and most complex networks.
“We welcome the court’s decision,” said Openet CEO Niall Norton, in a statement. “Openet’s long history of innovative development respects the intellectual property rights of others. This judgement vindicates our strategy of innovation over litigation. I would like to express our sincere appreciation for the tireless efforts of our staff and legal team during this process.”Openet Mediation enables the efficient analysis of data that would otherwise be too voluminous and varied to process. “Amdocs’ action shows it regards Openet as a serious competitive threat,” said Openet founder and CTO Joe Hogan (News - Alert). “Customers choose Openet because we channel our energy into creating better products instead of into litigation. Today’s judgement again proves that serving customers through product innovation is ultimately the best business strategy.”Want to learn more about patents in the telecom industry? Then be sure to attend Synopsis Under IP/Patents Telecom Sourcing Conference (SUITS), collocated with ITEXPO Austin 2012 happening now in Austin, TX. Stay in touch with everything happening at SUITS. Follow us on Twitter.
Edited by Rachel Ramsey
LATEST LEGAL NEWS
Research and Markets: Heplisav: 1018 ISS Immunostimulatory Oligonucleotide with HBsAg (Prophylactic Hepatitis B Virus Vaccines) - Global Forecast and Market Analysis to 2022
Lieff Cabraser Reminds CytRx Corporation Investors of Upcoming Deadline in Class Action Litigation - CYTR
Amazon and HBO Ink Exclusive Multi-Year Deal to Bring Award-Winning HBO Programming to Prime Members